Golgipharma

Golgi Pharma is a Spanish biotechnology company focused on developing first-in-class therapies for neurodegenerative diseases by targeting Golgi apparatus dysfunction. A spin-off from the Spanish National Research Council (CSIC) and the Centro de Biología Molecular Severo Ochoa (CBM), the company leverages research into Golgi stress and fragmentation, which are early pathological markers in diseases like Huntington's. Their lead program involves small molecules designed to restore Golgi structure and function, potentially slowing or halting disease progression. The company is currently in the pre-clinical stage, supported by specialized venture capital from firms like BeAble Capital. By addressing cellular trafficking and structural integrity, Golgi Pharma aims to provide disease-modifying solutions for rare neurological conditions.